[Skip to Navigation]
June 3, 2019

Educating Physicians About Marijuana

Author Affiliations
  • 1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California
JAMA Intern Med. 2019;179(8):1017-1018. doi:10.1001/jamainternmed.2019.1529
Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    3 Comments for this article
    Education vs proselytization about marijuana
    John Coleman, MS, MA, PhD | Assistant Administrator for Operations (Retired), US Drug Enforcement Administration
    Dr. Morris gives a fair but disturbing account of the knowledge base among the medical profession as to the harms of marijuana. That more than a third of a site survey of resident physicians believed marijuana is FDA-approved (and, presumably, OK to prescribe for medical use) is very troubling for a public that depends on the knowledge and skill of their physicians for good health. The paucity of reputable research that Dr. Morris mentions is disappearing quickly as more and more articles are published by serious authors and journals on the dangers and risks associated with the use of marijuana. Regrettably, Dr. Morris failed to mention the burgeoning research on teratological effects of cannabis use and the alarming increases in the rates of certain birth defects in states where marijuana use has been "legalized" for recreation and medical use. Until recently, much, if not most, "research" in this field was biased by authors proselytizing about the virtues and benefits of marijuana. Citing each other as experts and publishing questionable and generally unreplicable findings, it's no wonder such confusion still exists about the serious side effects of marijuana. With the burgeoning of the commercial marijuana industry in the US, and the emergence of large capitalized sources, we may begin to see a rapid increase in the needed research that Dr. Morris suggests is essential. It is unacceptable in this day and age that physicians be expected to acquire their knowledge of this drug on the unverified appraisals of its users. Those appraisals more often than not will reflect the intoxicating or psychic effects of the drug rather than its therapeutic benefits, if any.
    National Council of State Board of Registered Nursing July 2018 Pre Licensure and APN curriculum Guidelines for Medical Marajuan
    Deborah Bolton, BSN,MSN | Deborah L.Bolton and Associates
    The professional publication July 2, 2018 Journal of Nursing Regulation , Vol. 9.Issue 2, has recognized the very issues put forth in the article, supporting literature review, and previous comment to make recommendations the development and implementation of evidenced-based curriculums. It is a start and I hope the medical and pharmacology academic communities move forward.
    Not Just Physicians, Budtenders Too (But Doctors Need Significantly More Training)
    Mitchell Colbert |
    Thank you Dr. Morris for your very well written and balanced article, that weighs both the potential positives and negatives of cannabis use, while also being clear on the limits of our knowledge.

    As someone who as presented at CME courses offered to doctors on cannabis, there are not remotely enough opportunities for physicians to learn about cannabis. Although CME courses are better than nothing, doctors need to learn about the endocannabinoid system and clinical endocannabinoid deficiency while they are in school, and still have the chance to pursue research on it. Doctors should not be learning about
    cannabis from their patients, they should be educating those patients about it. When I broke my wrist and was curious if cannabis use would delay my healing, my doctor listened to me talk about cannabis and told me "you sound like you know this better than I do, use your best judgment." Can you imagine a doctor saying that about opioids?

    Doctors, nurses, pharmacists, and other health professionals are just one piece of this. Increasingly, the first person a would-be cannabis patient speaks to about their cannabis use is the budtender (or wellness consultant) at the dispensary where they are going to buy that cannabis. As a former wellness consultant who has educated over 25,000 patients about their cannabis use, it is clear that our budtenders need a better understanding of the science of this plant as well. Several times a week I would have patients coming in on pharmaceutical drugs with *known* drug to drug interactions that their physician(s) did not disclose to them. I only knew about the drug interactions because I did my due diligence and looked them up online, for every patient on medication. The main thing I was looking for is CYP 450 interactions because research shows that CBD can impact the CYP system in a similar manner to grapefruit juice (perhaps even more, perhaps less, we don't know yet).

    This is why I am pushing, not just for better training of our medical professionals, but some sort of standardized training for dispensary employees.